Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic Neuron Grafts in the Rat Model for Parkinson's Disease by Peng, Su-ping & Copray, Sjef
  
 University of Groningen
Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic Neuron Grafts in
the Rat Model for Parkinson's Disease
Peng, Su-ping; Copray, Sjef
Published in:
Stem cell reviews and reports
DOI:
10.1007/s12015-015-9623-7
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2016
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Peng, S., & Copray, S. (2016). Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic
Neuron Grafts in the Rat Model for Parkinson's Disease. Stem cell reviews and reports, 12(1), 105-120.
https://doi.org/10.1007/s12015-015-9623-7
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Su-Ping Peng1,2 & Sjef Copray2
Published online: 5 October 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Neuronal degeneration within the substantia nigra
and the loss of the dopaminergic nigro-striatal pathway are the
major hallmarks of Parkinson’s disease (PD). Grafts of foetal
ventral mesencephalic (VM) dopaminergic (DA) neurons into
the striatum have been shown to be able to restore striatal
dopamine levels and to improve overall PD symptoms.
However, human foetus-derived cell grafts are not feasible
for clinical application. Autologous induced pluripotent stem
cell (iPS cell)-derived DA neurons are emerging as an unprec-
edented alternative. In this review, we summarize and com-
pare the efficacy of human iPS cell-derived DA neuron grafts
to restore normal behaviour in a rat model for PD with that of
human foetal primary DA neurons. The differences we ob-
served in the efficacy to restore normal function between the
2 types of DA neuron grafts could be ascribed to intrinsic
properties of the iPS cell-derived DA neurons that critically
affected survival and proper neurite extension in the striatum
after implantation.
Keywords iPS cells . Ventral mesencephalic dopaminergic
neurons . Foetal tissue . Neurite extension and Parkinson’s
disease
Introduction
Parkinson’s disease (PD) is one of the most prevalent neuro-
degenerative diseases, affecting 1 in 100 people over the age
of 60 [1]. The disturbances in the initiation and fine-regulation
of movement resulting in tremor, rigidity, akinesia and postur-
al instability in PD patients are caused by the progressive loss
of dopaminergic (DA) neurons in the substantia nigra (SN).
The loss of DA neurons in the SN leads to a disruption of the
nigro-striatal circuitry and a dopaminergic depletion of the
striatum. The current standard therapy, L-DOPA administra-
tion, only temporarily restores striatal dopamine levels where-
as deep brain stimulation only transiently reduces severe trem-
or [2, 3].
The search for more efficient and long-term effective treat-
ment strategies for PD is still ongoing. The ground-breaking
developments in stem cell research in the last decade have
revived the interest for intracerebral cell transplantation as a
therapeutical approach for PD. In this approach, replacement
of the lost nigrostriatal dopaminergic innervation of the stria-
tum by exogenous dopaminergic neurons is intended to re-
store basic dopamine levels within the striatum. Experiments
on rodent and non-human primate models for PD in the 1970s
and 1980s, had shown that embryonic DA neurons could sur-
vive and reinnervate the striatum after stereotactic injection [4,
5]; moreover, reduction in drug-induced rotation behaviour
in’Parkinsonian’ rats demonstrated that the grafted DA neu-
rons indeed functionally integrated into the striatum and re-
leased dopamine [6–8]. Based on the findings in the experi-
mental animal models, various clinical trials were started in
the 1980s and 1990s with the striatal implantation of human
foetal DA neurons with promising results. Patients with hu-
man foetal ventral mesencephalon (VM) grafts have been
shown to recover from rigidity and tremors to various degrees,
correlated to the restoration of intracerebral dopamine levels
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as detected by PET [9–11]; many of these patients experi-
enced an overall improvement in quality of life [9, 10, 12,
13]. Though the outcome of striatal implantation of human
foetal DA neurons in a large group of PD patients was very
promising, reports on severe side effects, presumably due to
suboptimal, poorly documented graft composition and/or ad-
verse implant localization, led to a discontinuance of this ap-
proach. Apart from the complicated logistics to obtain multi-
ple donor foetuses of the same developmental stage, the use of
abortion-derived human foetal brain tissue to obtain a suffi-
cient number of homogenous graftable DA neurons raised
considerable ethical concern.
Several other sources for implantable human DA neurons
have been explored ever since. DA neurons have been suc-
cessfully differentiated in-vitro from human embryonic stem
(ES) cells and human neural stem cells (NSCs). Besides the
fact that both sources still caused ethical objections, the non-
autologous origin of these cells, demanding lifelong immuno-
suppression after implantation, was considered a major obsta-
cle. The ground-breaking detection of induced pluripotent
stem cells (iPS cells) generated from easily accessible somatic
cells (e.g. skin fibroblasts) [14, 15] has provided an unprece-
dented novel autologous source for human DA neuron grafts.
The functionality of these in-vitro generated human DA neu-
rons after intrastriatal implantation have been recently studied
in rodent and non-human primate models for Parkinson’s dis-
ease: in general, apart from the assessment of motor behav-
iour, parameters such as neuronal survival, the extent of
neurite outgrowth, the coverage of the striatum with a fine
network of dopaminergic terminals and the release of dopa-
mine have been evaluated.
The aim of this review is to summarize the behavioural
effects, the survival and neurite outgrowth of human iPS
cell-derived DA neurons after their intrastriatal implantation
in the Parkinson rat model and compare them with those ob-
served for implanted human primary foetal DA neurons. We
discuss possible explanations for the differences in efficacy,
survival and outgrowth between the iPS cell-derived DA neu-
ron grafts and the primary DA neuron grafts.
Unilateral 6-OHDA Lesion Rat Model
for Parkinson’s Disease
In order to study the feasibility and efficacy of grafted DA
neurons as therapy for Parkinson’s disease, a proper animal
model is required. Among various animal models for PD (for
review see [16, 17]), 6-OHDA-lesioned rats are the most often
used PD animal model in DA neuron graft research. The toxin
6-hydroxy-dopamine (6-OHDA) specifically uses the cate-
cholamine transport system of catecholaminergic neurons to
enter the cells. It generates hydrogen peroxide and hydroxyl
radicals and disturbs mitochondrial complex I, which leads to
the production of superoxide free radicals and eventually to
cell death. Stereotactical injection of 6-OHDA into the stria-
tum of an adult rat, will induce retrograde degeneration of the
SN DA neurons, usually within 2 to 3 weeks [18]. When the
injection of 6-OHDA is directed into the nigrostriatal tract or
in the SN itself, acute DA neuron death will be induced within
24 h [19]. The size of the lesion can be adjusted by varying the
dosage of 6-OHDA [18]. The efficacy of the unilateral 6-
OHDA induced lesion and so the effect of a specific treatment
in rats are validated by ipsilateral or contralateral circling mo-
tor behaviour after the administration of amphetamine or apo-
morphine [20]. The number of rotations per minute can be
taken as a measure for the severity of unilateral DA loss in
the striatum and the efficacy of compensation by DA-
producing grafted DA neurons [21]. Besides drug-induced
rotation, 6-OHDA unilateral lesions of the rodent meso-
telencephalic dopamine pathways also lead to postural curva-
ture, spontaneous rotation, contralateral sensory neglect and
aberrant activity [7, 22]. Various activity tests, such as the
adjusting step test [23] and the cylinder test [24], have been
used to study the non-rotational behavioural consequence of
the 6-OHDA unilateral lesions and the effects of a specific
treatment on that.
Human Foetal Dopaminergic Neuronal Grafts
Since the late 1970s, transplantation of embryonic VM tissue
from rodents and primates in PD animal models has been exten-
sively studied (for reviews see [25, 26]). From these fundamental
studies, protocols for transplantation were established as para-
digm for studies on human foetal tissue transplantation. It was
established that only newly formed postmitotic DAneurons (E13
- E15 in rats) are suitable for grafting, since they have just
reached a dopaminergic phenotype but do not yet have fully
outgrown extensions, which makes it possible to isolate them
without too much cellular damage [21, 27]. Extrapolating these
data to human DA neuron grafts, human foetal VM tissue of a
gestational age of 7 to 10 weeks was considered optimal. In
almost all rodent studies, transplantation was performed right
after tissue isolation and preparation, either dissociated into cell
suspension or dissected as small tissue pieces. In this approach,
DA neurons appeared to be still viable and survive the grafting
procedure [26, 28].
Based on the promising data of rodent and primate DA
neuron-rich VM tissue transplanted into PD models [4, 8,
21, 29–31], experimental studies with the implantation of hu-
man foetal DA neurons in PD models were started.
Cellular Composition
When isolating and dissociating the foetal human ‘DA’ VM
region for Parkinson-related transplantation purposes, one
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should be aware of the actual cellular composition of this
region. This is of considerable importance since in most PD
transplantation studies foetal human VM cell suspensions
have been used without any form of purification. In the human
(foetal) VM region, SN DA neurons and ventral tegmentum
area (VTA) DA neurons indeed make up around 70 % of the
neurons [32]. About 30 % of the neurons are GABAergic; in
addition 2–3 % of glutamatergic (Glu) neurons can be found
in this region [32]. However, one should be aware that neu-
rons account for only 5.6 % of the total number of cells in the
VM, which is even less than in most other brain areas, for
instance the brain stem; 8 % of the cells in this area are neu-
rons [33]. Most of the cells in the VM region are nonneuronal
and comprise astrocytes, microglia, endothelial cells etc.…
The contamination of all these specific nonneuronal cell types
in the ultimate graft will inevitably affect the survival and
function of the implanted DA neurons and the reaction of
the host in the environment around the graft. So, in fact, only
a minority of cells in the non-purified foetal cell suspension
from the human VM region, isolated for grafting in PD animal
models, can be actually considered SN dopaminergic neurons.
When human VM tissue grafts are collected from aborted
foetuses, the cellular composition may be even more uncer-
tain, due to the method of abortion used. In many cases, the
abortion procedures led to a destruction of the foetus, which
made it difficult to recognize brain tissue, let alone the very
small specific VM portion. Even contaminating serotonergic
(!) neurons have been demonstrated in the periphery of the
grafts in the study by Stromberg in 1989 [34]: many 5-HT-
immunoreactive terminals were found in the striatal neuropil
of the host brain arising from the graft. Most studies do not
even report or discuss the cell composition of the used human
foetal DA neuron grafts.
Efficacy of Intrastriatally Grafted Human Foetal DA
Neurons in PD Animal Models
Behavioural Improvement and DA Neuron Survival
In most studies on human foetal VM tissue transplantation in
the unilaterally 6-OHDA lesion rat PD model (Table 1), a
significant reduction in drug-induced rotation was observed
either after grafting with a VM-derived cell suspension or
small VM tissue pieces. In two rats, in the study by Brundin
et al., rotation was completely annihilated and even contralat-
eral rotation was induced at 12.5 weeks post grafting. Another
two rats in this study reduced amphetamine-induced rotation
by 69 and 92 % at week 15.5 post grafting [35]. Rotation
reduction appeared to be correlated with the number of sur-
viving DA neurons: complete recovery was established by an
average of 1200DA neurons 21weeks post grafting, while the
14 to 107 DA neurons found in some rats were unable to
induce any behavioural change [35]. The behavioural
improvement after human DA grafting occurred much later
than what was observed with rat embryonic VM tissue grafts
(3–4 weeks post grafting), indicating that human neurons re-
quired more time to mature and integrate into the striatum.
Reduction in drug-induced rotation was only observed
15.5 weeks post grafting in rats receiving a human VM cell
suspension from foetuses of gestational age of 9 weeks (PC
9 weeks), but not from foetuses isolated at gestational age
between PC 11–19 weeks [35]. In another experiment with a
similar set-up, intrastriatal grafting of human VM tissue with a
gestational age of 6.5 weeks and 8 weeks resulted in a pro-
nounced reduction in both amphetamine- and apomorphine-
induced rotation, as well as in spontaneous rotation 18 weeks
post grafting [37]. In these animals, 300 to 4249 (average
1626) DA neurons were found to survive in the grafted stria-
tum. The studies by Brundin et al. indicated that in general
between 1 and 10 % of the grafted human foetal VM cell
suspension (approximately 40,000 DA neurons) survived the
implantation procedure [35, 37]. Additional studies have
shown that the survival of between 500 and 700 human foetal
VM DA neurons are needed for full reversal of the
amphetamine-induced rotation behaviour by 19–21 weeks
post grafting [38, 44].
Transplantation of small VM tissue pieces in a premade
cavity in the cortex also yielded significant DA neuron sur-
vival and led to a significant reduction of drug-induced rota-
tion. In this approach, even human VM tissue pieces of a
gestational age up to 12 weeks could actually survive trans-
plantation and gave rise to a similar behavioural improvement
at 3–5 months post grafting as the cell suspension grafts [34,
36]. The generation of human VM DA neurons takes place
during post conception week 6.5 to 9; they start extending
elaborated processes towards the striatum from week 10 on
[45]. It is apparent that the DA neurons in young explants (PC
6.5–9 weeks), since they do not have extensive axonal and
dendritic outgrowth, are hardly damaged during isolation and
dissociation; in contrast, older foetal DA neurons (PC 11–
19 weeks) already have extensive axons, dendrites and con-
nections, so most of them are severely damaged after dissoci-
ation and will not survive after implantation. When dissocia-
tion is omitted and small blocks of foetal VM tissue are used,
the structure of most cells will be preserved, so that even
tissues from PC 12 weeks can be used.
Full reversal of apomorphine-induced rotation was seldom
reported. Yet, Stromberg et al. showed that this is possible
with prolonged time, 7 months post grafting. The increase of
D2 and D3 receptors in the striatum seems to be normalized at
this time point [42]. It has been suggested that the function of
SN also depends on dendritic DA release in the SN [46].
Interestingly, transplantation of DA neurons in the SN can
give rise to a reduction of apomorphine-induced rotation
[44]. However, it is still controversial whether the DA neurons
grafted close to SN are able to extend through the meso-
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striatal pathway to reinnervate the striatum; whereas Rath
et al. [44] were unable to detect such connection, both
Wictorin et al. [41] and Grealish et al.[47] showed that grafts
of human foetal VM of different donor ages could indeed
reconstruct the meso-striatal pathway when grafted to SN of
adult 6-OHDA lesioned rats.
Characteristics of Transplanted Human Foetal DA Neurons
It was observed that human foetal DA neurons grafted in the
striatum needed a longer period to mature and integrate than
those from rodents. Two to three months post grafting, the
human TH+ neurons still had an immature small rounded cell
body. Up to 4 months, the DA neurons were more similar to
adult SN DA neurons with TH+ dendrites and often with fine
spine-like lateral processes [36]. Two main populations of
TH+ neurons were observed: the most frequent type with
small perikarya of diameter between 12 and 25 μm, and the
rest of the population with a large perikarya diameter up to
50 μm long [37, 38]. In some cases, TH+ perikarya were
found up to 1–1.5 mm from the graft borders in the host
striatum, indicating the ability of the grafted premature DA
neuroblasts to migrate [37]. Most of the neurons were multi-
polar with coarse processes extending 2.5–3.0 mm [34] into
the host striatum, and in some case, up to 6 mm [37] or even
9–10 mm [41, 44]. The extent of actual reinnervation of the
striatum correlated to the post grafting time. A sparse TH+
fibre plexus was seen adjacent to the implant 11 weeks post
grafting, while a rich strong TH+ fibre network appeared to
have reinnervated the entire striatum at 20 weeks (or longer)
post grafting [38, 40, 42, 43].
The demonstration of reciprocal synaptic connectivity be-
tween grafted human foetal DA neurons and the host striatal
interneurons confirmed the integration of the grafted human
foetal DA neurons. Ultrastructural studies identified the TH+
coarse processes as dendrites [38], providing a site for host
input to the graft: graft-derived TH+ dendrites appeared to
receive non-TH labelled synaptic contacts in the host striatal
neuropil. Moreover, TH+ axons containing round or oval ves-
icles formed symmetric synapses, like those seen in the nor-
mal meso-striatal DA pathway, with dendritic shafts and
spines and in an even higher incidence on neuronal perikarya
[34, 38, 39].
The electrophysiological characteristics of grafted human
DA neurons were similar to those of DA neurons in an intact
rat, which fire spontaneously in a slow firing rate (1–10 Hz)
[48]. Some of the grafted human DA neurons showed the
characteristic features of initially positively deflecting, bi- or
triphasic action potentialswith durations greater than 1.5msec.
The sustained activity rate of these DA neurons ranged be-
tween 0.1 and 10 spikes per second. As also found in the intact
rat, some ‘partially active’ grafted human DA neurons
exhibited action potential waveforms that were consistent with
the waveforms recorded from in situ active DA neurons [40].
The functionality of the synapses formed by the grafted
human DA neurons with the host striatal interneurons was
validated with striatal recordings. The striatal interneurons at
the site of the human foetal graft displayed slow discharge
rates (3.1±0.4 spikes/s) that were almost identical to those
found in striatal neurons at the nonlesioned site (mean 3.0±
0.4 spikes/s) [40].
Intracerebral dialysis showed that the basal level of dopa-
mine in the grafted striatum (0.26±0.08 pmol per 25 μl of
sample perfusate) of the 6-OHDA lesion rat was restored to
the level observed in intact striatum (0.19±0.06 pmol per
25 μl of sample perfusate). Grafted human DA neurons were
able to respond to amphetamine stimulation with a significant
increase in the DA level of the grafted striatum (3.7 times
increase), although this increase was less pronounced than that
observed in intact striatum (15.1 times increase) [37].
Application of Human Foetal VM Tissue Transplantation
in Parkinson Patients
The promising results of intracerebral implantation of human
foetal VM DA neurons in the rat model for Parkinson’s dis-
ease led to open clinical trials in Parkinson patients. In these
open clinical trials, many patients with human foetal VM
grafts recovered from rigidity and tremors in various degrees,
correlated to the restoration of the striatal dopamine level de-
tected by PET [9–11]; the patients experienced an overall
improvement in life quality [9, 10, 12, 13]. Occasional post
mortem studies showed the survival of DA neurons at the graft
sites (between 80,000 and 135,000 TH+ neurons), and exten-
sive reinnervation of the striatum [49, 50]. The positive results
of these initial open clinical trials sharply contrasted with the
results of double-blind control NIH studies (reviewed by
[51–53]): these studies failed to show any significant benefit
in grafted patients up to 1 and 2 years in follow-up studies.
Moreover, approximately 15 % of the grafted patients in NIH
study I and 56 % in study II experienced severe graft-induced
dyskinesias [54, 55]. The major differences in the outcome of
graft treatment between the more accurate double-blind con-
trol NIH studies and the non-standardized open trials could be
ascribed to major differences in the selection of patients, in the
preparation, the storage, the final composition and the size of
the human foetal cell graft, the site of intrastriatal deposition
and the assessment methods. Although the impure composi-
tion of the human foetal grafts did not seem to prevent signif-
icant rotation reductions in the Ungerstedt rat model for
Parkinson, it may be of major relevance for clinical applica-
tion. Apparently, the complex architecture, composition, size
and regional differences in functionality of the human striatum
represent a completely different niche than the smaller, less
complicated striatum of the rat. Recently, a number of post-
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mortem brain analyses were performed on Parkinson patients
that received a foetal DA graft from 3 up to 16 years ago and
more of such analyses are expected in the near future. Such
analyses revealed the extent of survival and the cellular com-
position of the graft. The first data clearly showed that the
grafted dopaminergic neurons were integrated in the striatal
circuitry; in addition, interestingly, some of the grafted DA
neurons appeared to have developed a Lewy body pathology
pointing to a prion-like transfer from surrounding cells of the
responsible pathogen, most likely alpha-synuclein [56–58].
It is clear that the development of autologous induced plu-
ripotent stem cells has now provided an unrestricted source of
graftable human DA neurons that can be extensively charac-
terized and stringently purified before actual implantation in
the Parkinson patients. Clinical application of these iPS cell-
derived DA grafts in the near future can benefit from the
ample practical experience with human foetal DA neuron
intrastriatal implantations, despite their much-debated out-
come. However, before clinical application, it needs to be
established that DA neurons differentiated from human iPS
cells show similar survival and neurite outgrowth after im-
plantation in the PD animal models with a similar (or even a
more pronounced) behavioural improvement as the primary
foetal human DA neurons.
Human iPS Cell-Derived Dopaminergic Neuron
Grafts
Reprogramming of human fibroblasts towards iPS cells in-
volves a complete epigenetic resetting and a concomitant
complete cellular rejuvenation. Subsequent in-vitro differenti-
ation and maturation of human iPS cells towards a dopami-
nergic cell lineage will yield foetal DA neurons, with a matu-
rational stage comparable to the human DA neurons isolated
from aborted foetuses. Proper DA differentiation largely de-
pends on the completeness of the reprogramming process and
on the in-vitro protocol used for differentiation. Such a proto-
col should meticulously recapitulate the normal embryonic
development of DA neurons, mimicking the local micro-en-
vironment. Extensive characterization and purification should
lead to a much better defined DA neuron cell suspension for
implantation in comparison to the human foetal primary DA
cell grafts.
Cellular Composition of Human iPS Cell-Derived
Dopaminergic Neuronal Graft
In order to generate proper VM DA neurons in-vitro from
hiPS cells, three different differentiation strategies have been
applied that have been developed for embryonic stem cells
(ES Cells): the embryonic body (EB) method [59], the stromal
cell co-culture method [60] and the defined-medium floor
plate induced method [61] (for reviews see [62–66]). The
representative procedure of each differentiation method and
the expression of VM DA neuronal markers in differentiated
cells are summarized in Fig. 1. Recently, several hiPS DA-
differentiation protocols have been forwarded but in general
they are just modifications of the 3 mentioned strategies
[67–69].
The EB-based differentiation protocol starts with the spon-
taneous differentiation of cultured iPS cells into EBs contain-
ing the 3 germ lineages and is followed by the selective en-
richment of the neuroectoderm and the neural precursors [59].
The stromal cell co-culture method is based on the stromal
cell-derived inducing activity (SDIA) that has been shown to
promote neural differentiation of ESCs [70]. In both methods,
neural rosette structures are formed, which are composed of
neuroepithelial cells [71, 72]. The defined-medium floor plate
induced method employs dual inhibition of SMAD signalling
by Noggin and SB431542 to force the differentiation of hu-
man ES Cells and iPS cells into a neural cell lineage [73].
Early exposure to SHH from day 1 of differentiation directs
the iPS cells to a floor plate fate [74], and in combination with
the WNT signalling activator CHIR99021 (CHIR), typical
VM DA neuron precursors that co-express FOXA2 and
LMX1a are generated [70]. With this method, more than
70 % of the cells can be committed to a floor plate cell fate
[74, 75]. The neuroepithelial cells and floor plate precursors
can be induced to a VM DA neuronal fate by combination of
the induction factors SHH and FGF8.
The in-vitro properties of the generated DA neurons were
shown to vary between the different differentiation methods.
All differentiated DA neurons were reported to be TH+ and to
co-express major VM DA neuron markers NURR1, GIRK2,
PITX3 etc. [73, 75, 76]; dopamine release and slow autono-
mous pace-making spontaneous synaptic activity was also
reported [68, 77]. However, in contrast to the floor plate in-
duced protocol [78, 79], both the embryonic body (EB) meth-
od and the stromal cell co-culture method, failed to induce
FOXA2 express ion dur ing neuroepi the l ia l ce l l -
differentiation [47]. This later developed protocol was de-
signed to firstly direct pluripotent cells towards floor plate
cells before induction of VM DA neurons which is more sim-
ilar to the in-vivo VMDA neuron development [80]. It seems
the floor plate-derived DA neurons are more authentic to pri-
mary VM DA neurons [47]. Apart from more precise specifi-
cation and higher efficiency, direct comparison of rosette-
neuroepithelial cell-derived and floor plate cell derived DA
neurons post grafting also favoured floor plate-derived DA
neurons [61].
Unlike transplantation studies with human foetal VM tis-
sue, the composition of the iPS cell-derived DA neuron grafts
has been well described. By the end of in-vitro differentiation,
the percentage of TH+ DA neurons derived from iPS cells
varied considerably, dependent on the differentiation method
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used [61, 75–77, 81]. In the study by Hargus et al., 5–10 % of
the total number of differentiated cells were neurons positive
for tyrosine hydroxylase (TH): less than 1 % of the TH+
neurons co-expressed dopamine-β-hydroxylase (DBH), indi-
cating that the vast majority of the TH+ neurons were DA and
not noradrenergic neurons [82]. Rhee et al. reported that 50–
60 % of all differentiated cells were TUJ+, of which 35–45 %
were TH+ [76], whereas Kikuchi and colleagues described
that, with their approach, most of the differentiated cells were
TUJ+, with 85 % being TH+ [83]. Other studies reported TH-
expression in 18 to 54% of FOXA2+ cells after differentiation
[61, 75]. A small contamination with serotonergic,
GABAergic and glutamatergic neurons and GFAP+ astrocytes
were often detected [61, 76, 77]. In general, only sporadically,
undifferentiated iPS cells (indicated by the expression of
SSEAs, typical pluripotency cell markers) were detected after
long term differentiation [77, 82] and also a few Ki67+ pro-
liferating cells [61, 75, 82].
Efficacy of Intrastriatally Grafted Human iPS
Cell-Derived DA Neurons in PD Animal Models
Behavioural Improvement and DA Neuron Survival
The studies of human iPS cell-derived DA neuron transplan-
tation in the rat PD model are summarized in Table 2. The
reduction in rotation behaviour in the unilaterally lesioned 6-
OHDA rats strongly depends on the number of surviving,
integrating, dopamine-producing grafted neurons. Whereas
between 500 and 700 surviving foetal VM graft derived DA
neurons have been shown to be sufficient to completely anni-
hilate amphetamine-induced rotation activity, as many as 29,
000 surviving human iPS cell-derived DA neurons appeared
to be able to induce only a 50 % reduction in drug-induced
rotation 4 weeks post grafting; less than 1500 surviving hu-
man iPS cell-derived DA neurons resulted in not any signifi-
cant change in rotation behaviour. Rhee et al. reported that
around 27,000 surviving TH+ cells were found in the 6-
OHDA-lesioned rats that exhibited a 47.5 % reduction in ro-
tations 8 weeks post grafting [76]. In the study by Hargus
et al., the survival and integration of around 5000 human
iPS cell-derived DA neurons led to a reduction in rotation of
only 56 % 16 weeks post grafting [82]; these rats still did not
show any improvement in the cylinder test and the adjustment
stepping test [82]. The same study showed that rats containing
only 350 surviving iPS cell-derived TH+ cells did not show
any functional improvement in apomorphine-induced rotation
[82]. Similarly, the survival of around 6700 human iPS cell-
derived DA neurons reduced rotation behaviour to 78 %
16 weeks post grafting in a study by Doi et al. [75]. Kriks
et al. showed that 15,000 surviving human iPS cell-derived
TH+ DA neurons could fully compensate or even reverse
amphetamine-induced rotation and improved the performance
in cylinder test and stepping test 20 weeks post grafting [61].
In general, a much greater number of surviving TH+ DA
neurons derived from human iPS cells is needed to give rise
to significant functional improvement in comparison to hu-
man foetal DA neurons.
In most studies, between 200,000 and 400,000 human iPS
cell-derived cells were stereotactically transplanted in the
Fig. 1 Schematic summary of
the conditions for DA neuron
differentiation in the
representative protocols.
Respectively for the EB method,
the stromal cell co-culture method
and the floor plate method. Based
on [59] (EB), [60] (co-culture)
and [61] (floor plate)
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denervated striatum of the unilaterally 6-OHDA lesioned rats.
Cells were transplantedmainly at two stages of differentiation.
Transplantations executed with cells at the late stage of termi-
nal differentiation resulted in a highly variable percentages of
surviving DA neurons: from 0 % [76], to only 1.1 % [75], and
5–10 % [82]. In some studies, human iPS cell-derived cells
were transplanted at an early stage of dopaminergic differen-
tiation, containing predominantly neural precursor cells and
only a very few TH+ cells [75]. Such grafted neural precursor
cells, already destined towards a VM DA neuron fate, could
still proliferate before final differentiation into mature DA
neuron in-situ and gave rise to a much larger (yet unpredict-
able) number of TH+ cells: 6700 [75], 15,000 [61] and 27,000
[76] TH+ cells were found within grafts. The graft size in
these studies was usually much bigger than that of terminal
differentiation stage implantations [75, 76]. The continuing
proliferation of the neural precursor cells could result in over-
growth [76], and the early stage of differentiation could lead to
the presence of undifferentiated iPS cells and so teratoma
formation.
Characteristics of Transplanted Human iPS Cell-Derived DA
Neurons
Analysis of the human iPS cell-derived grafts in the denervat-
ed striatum of the 6-OHDA lesion rats revealed TH+ DA neu-
rons that were also positive for specific VM DA neuron
markers, such as EN1, VMAT2, DAT [76] NURR1 [76],
GIRK2, PITX3 [75, 83], and FOXA2 [61]. A detailed charac-
terization of surviving human iPS cell-derived DA neurons
showed that 53.4±6.6 % of the TH+ cells were GIRK2+ VM
DA neurons, 4.7±1.0 % were GABA+ forebrain DA neurons,
and 5.8±1.2%were NKX2.1+ hypothalamic DA neurons [82].
However, it should be noted that in most studies the TH+ DA
neurons were actually only a small portion of the surviving
human iPS cell-derived cells. The majority of the iPS cell-
derived neurons appeared to be non-DA [76, 77, 82]; some
were identified as serotonergic, GABAergic neurons [61, 76,
77]. GFAP+ astrocytes were also found within the grafts [76,
82]. Oligodendrocytes were never found, probably due to their
very specific late generation during embryonic development
and the consequently long specific in-vitro differentiation pro-
cedure required [76]. Ki-67+ proliferating cells could still be
found in the intrastriatal graft [82]. Contamination of these cells
may lead to graft overgrowth [76] or teratoma formation.When
dopaminergic neural precursor cells were enriched by sorting
for NCAM [69] or CORIN [75], graft overgrowth and teratoma
formation were significantly reduced. No ubiquitin-positive
and/or α-synuclein–positive inclusion bodies could be detected
in grafted iPS cell-derived DA and non-DA neurons generated
from fibroblasts of PD patients up to 12 weeks post grafting
[82]. Remarkably, exogenous pluripotent gene (OCT4,
NANOG and SOX2) expression persisted in subpopulations of
TUJ1+ neuronal cells and TH+ DA neurons derived from
lentivirally reprogrammed hiPS cells even after terminal differ-
entiation [76]. In the study described by Hargus et al. engrafted
human iPS cell-derived DA neurons showed intense
arborisation and branching, yet most of the DA neurons sent
TH+ fibres only towards other cells within the grafts and did not
extend out to the surrounding parenchyma [82]. Kriks et al.
reported that the graft core was surrounded by a halo of TH+
fibres, with some fibres occasionally extending up to 3 mm
from the graft [61]. Non-TH+ neurites were found to project
to their target areas according to their intrinsic phenotypic de-
termination in specific and reproducible patterns [82]. In acute
organotypic slices prepared from grafted rats, all transplanted
neurons recorded showed spontaneous action potential
currents.
Human iPS Cell-Derived DA Neurons for Clinical Studies
Based on the animal studies on cell replacement therapy for
Parkinson’s disease, there is no doubt that iPS cells are a
prominent source for transplantable DA neurons, but the pro-
cedure to generate VM DA neurons from iPS cells in-vitro is
as yet not acceptable for clinical application. A reliable quality
check for human iPS cell-derived DA neurons is yet to be
established. iPSC lines vary from one another both in
pluripotency and differentiation efficiency [84], which may
also dependent on passage number [85]. Although iPS cells
resemble ESCs, a comparative study showed that some iPSC
lines have a delayed formation of EBs in comparison to ESCs
[85]. Different reprogramming methods may also affect the
quality of iPS cell-derived DA neurons [86]. Rhee et al. found
that exogenous pluripotent genes were not completely si-
lenced at the end of the differentiation procedure. OCT4, as
well as NANOG, was still detectable in subpopulations of
TUJ1+ neuronal cells and TH+ DA neurons derived from
lentivirally reprogrammed hiPS cells, but not in those derived
from retrovirally reprogrammed hiPS cells or protein-transfer
reprogrammed hiPS cells [76]. Furthermore, unlike those
from protein-transfer reprogrammed hiPS cells, NP cells de-
rived from virally-reprogrammed hiPS cells exhibited early
senescence and apoptotic cell death during passaging, which
was preceded by abrupt induction of p53 [76]. The variation in
iPSC lines may affect the efficiency in both DA neuron dif-
ferentiation and their survival post grafting.
General standards for human iPS cell-derived functional
and authentic VM DA neurons are yet to be established. It is
apparent that the much higher number of human iPS cell-
derived DA neurons to achieve the same degree of functional
improvement as that of human foetal VM DA neurons is re-
lated to the quality of the TH+ cells derived from human iPS
cells. The (as yet not generally standardized) validation of
human iPS cell-derived VM DA neurons is based on the ex-
pression of (a combination of) specific VM DA neuron
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markers, such as the co-expression of TH, LMX1A and
FOXA2 [61], the co-expression of TH and GIRK2 [81], the
co-expression of TH and EN1, NURR1 and PITX3, the lack
of dopamine beta-hydroxylase (DBH) co-expression with
TH+ cells [82], etc. In a few cases, the release of dopamine
and the electrophysiology of iPS cell-derived DA neurons
were used to confirm the resemblance with primary VM DA
neurons [61, 76, 87]. Contamination of other cell types within
the iPS cell-derived culture is a major concern, in that respect
similar to the human foetal VM cell grafts. The establishment
of a VM DA neuron purification method will be a break-
through for cell replacement therapy for PD, for it will elim-
inate the presence of proliferating cells and undifferentiated
iPS cells and reduce the risk of graft overgrowth or tumor
formation. By reducing the presence of other cell types, po-
tential cellular interactions and unknown effects of other neu-
ronal cell types on (rotation) behaviour will be avoided. PSA-
NCAM, a surface marker for neural stem/precursor cells, has
been used with FAC-sorting to enrich for neural precursors
[88] and floor plate-specific cell surface marker CORIN has
been used to enrich for hiPS cell-derived dopaminergic neu-
ronal precursors [75]. FAC-sorting on NCAM+/CD29low cells
was used by Sundberg et al. to enrich VM DA neurons [69].
Neither of these cell sorting methods resulted in a pure popu-
lation of mature VM DA neurons. An alternative approach
could be to generate reporter lines for DA neuronal differen-
tiation and use reporter expression for purification or selection
via FAC-sorting of human dopaminergic neurons by clinically
acceptable gene modification methods [89]. It is important to
note that FAC-sorting at the late stage of differentiation may
hamper the viability of cells post grafting. The number of
surviving DA neurons was reduced by more than 10 times
in the study by Hargus et al. [82].
Comparison of Human Foetal With Human iPS
Cell-Derived Dopaminergic Neuron Grafts
Transplantation of human foetal VM tissue in PD animal
models has provided proof-of-principle for DA neuron surviv-
al, outgrowth and integration as well as functional recovery of
the grafted animal. It may serve as a gold standard for evalu-
ating the quality of DA neurons derived from hiPS cells. We
summarized the performance of hiPS cell-derived DA neuron
grafts and compared it with that of human foetal VM tissue
grafts in the 6-OHDA lesion rat model (Table 3). The number
of surviving implanted TH+ neurons ranged from a few hun-
dred to around 4000 per graft in rats grafted with human foetal
VM tissue. About 500–700 of viable functional DA neurons
appeared to be sufficient to reverse drug-induced rotation un-
der optimal surgery conditions [38, 44]. On the contrary, sur-
vival of TH+ cells from iPS cell-derived dopaminergic neuron
grafts ranged from a few to 29,000. In contrast to the human
foetal DA grafts, thousands of iPS cell-derived TH+ cells
appeared to be needed to fully reverse drug-induced rotation
[61, 75].
Primary DA neurons from foetal VM tissue gave rise to
extensive neurite outgrowth up to 6 mm [37] and reinnervated
the whole volume of the striatum (Fig. 2a) [38, 40]. Neurite
outgrowth of iPS cell-derived DA neurons varies from case to
case but, in general, it remained relatively limited [82] or
extended only 2–3 mm into the striatum, reinnervating only
around 10 % of the striatum, despite the large number of
surviving TH+ neurons (Fig. 2b) [61, 75]. It seems likely that
the more limited survival and neurite outgrowth of grafted
hiPS cell-derived DA neurons in comparison to the primary
human foetal DA neurons, is responsible for a lower degree of
recovery of the 6-OHDA lesion rats in the drug-induced rota-
tion behaviour. In contrast to hESC-derived DA neurons [90],
data about dopamine release or the electrophysiological char-
acteristics of hiPS cell-derived DA neurons integrated in the
striatum after grafting are not yet available.
Conclusions
Although the human iPS cell-derived DA neurons seem to
fulfil the major criteria for functional dopamine-releasing neu-
rons, it is clear that they were not as effective as the human
primary (foetal) DA neurons in restoring drug-induced rota-
tion behaviour in the unilaterally 6-OHDA lesion rats. Amuch
higher number of surviving DA neurons were required to
obtain the same behavioural effects of the primary foetal DA
neuron grafts. The human iPS cell-derived DA neurons
showed a lower survival rate after striatal implantation and
their neurite outgrowth was not as extensive as that of the
human primary foetal DA neurons. Apparently, the human
DA neurons obtained via differentiation from iPS cells were
not identical to the primary DA neurons isolated from the VM
region of the aborted foetuses. Indeed, after the
reprogramming-associated complete juvenation, the iPS cell-
derived DA neuron may also be considered foetal, but the
differentiation protocol most likely did not result in the very
specific population of foetal A9 DA neurons that have the
specific intrinsic properties to innervate the striatum. It is like-
ly that, after the drastic iPS cell-reprogramming and the sub-
sequent dopaminergic differentiation, fibroblast-derived epi-
genetic marks were still present interfering with a proper com-
plete reprogramming and DA differentiation. In that respect, it
is of considerable interest to note that DA neurons differenti-
ated from human ESCs (with a similar protocol used for hiPS
cells) recently showed long-term survival, efficacy in restora-
tion of motor function as well as long extensive neurite out-
growth and wide striatal innervation after implantation in the
rat PD model with a potency comparable to that seen with
human foetal dopamine neurons [91]. Recently, we performed
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an in-depth comparative analysis of the expression profile of
pure mouse iPS cell-derived DA neurons with that of pure
mouse primary DA neurons [92]. We used Ptix3-GFP mice
to enable the isolation of pure iPS cell-derived DA neurons
and pure primary VM DA neurons with GFP-based FAC-
sorting. Besides comparative global gene expression map-
ping, we performed comprehensive DNA methylation profil-
ing by Reduced Representation Bisulfite Sequencing (RRBS).
The mouse iPS cell-derived DA neurons indeed largely ap-
peared to adopt characteristics of their in vivo counterparts, in
morphology, dopamine production, global gene expression
and CpG island (CGI) methylation profiles, though some fi-
broblast genes appeared to be expressed still [92]. However,
we also found deviations in CGI methylation for a subpopu-
lation of genes which clearly effected predominately the ex-
pression of genes associated with functional annotations such
as Bnervous system development^, Bneurogenesis^ and
Bneuron differentiation and outgrowth^ [92]. It is likely that
similar iPS reprogramming Bartefacts^may be responsible for
the limited outgrowth and survival of the human iPS cell-
derived DA neurons after implantation in the rat Parkinson
model. Extensive comparative expression profiling combined
with genome wide epigenome analysis, like we have done for
the mouse, is needed to examine in more detail the differences
between human primary foetal DA neurons and the human
iPS cell-derived DA neurons, although proper purification of
human DA neurons may still be a bottle neck for that.
In view of the considerable undeniable clinical potential of
(autologous) human iPS cell-derived DA neuron grafts, fun-
damental and preclinical research is still progressing which
will eventually lead to a first clinical trial on a small number
of Parkinson patients, presumably within 2 years. Important
Fig. 2 Comparison of grafted human foetal VM tissue and hiPS cell-
derived DA neurons. a Overview of TH+ neurites in a coronal section of
the striatum 4 months after grafting human foetal VM tissue from a 10-
week-old foetus. The graft, filled with TH+ cell bodies and fibres is seen
at the far right, TH+ processes radiate into host striatum and form a
network that covers the whole area of striatum. b Overview of TH+ iPS
cell-derived DA neurons (unsorted) 4 months after intrastriatal
transplantation. Higher magnification showing TH-positive somata and
some innervation of the surrounding host striatum by graft-derived
neurites (b) Scale bar = 200 μm, CC = corpus callosum, V = ventricle.
Adapted from [40, 75]
Table 3 Comparison of major parameters of (non-purified) human foetal and human iPSC-derived dopaminergic grafts in rat PD model
Human foetal DA graft Human iPSC-derived DA graft
Composition DA neurons, 5-HT neurons, GABAergic
neurons, astrocytes, microglia [32, 34]
DA neurons, NSCs, undifferentiated iPSCs
serotonergic, GABAergic neurons astrocytes
[75–77, 81, 82]
Percentage DA neurons in original graft 5.6 % [32, 33] 5–85 % [61, 75–77, 81, 82]
Survival ++++ 1–10 % [35, 37] +++ 0–12 % [75, 76, 82]
Graft overgrowth – ++ [76]
Migration + [37] not detected
Neurite outgrowth Long extensions [34, 36, 38, 40, 44] Short extensions [61, 82]
Synaps formation ++ [34, 38] not detected
Recovery (rotation reduction, other tests) ++++ [35, 38, 44] ++ [75, 76]
Minimal number of TH+ cells required to full
reversion of rotation behaviour
500–700 [38, 44] 15,000 [61]
Co-expression of VM DA markers in surviving
DA neurons
FOXA2+, LMX1a+, EN1+, NURR1+,
GIRK2+, TH+ [47, 69]
TH+, GIRK2+, EN1+, NURR1+, LMX1A+,
and PITX3+ [61, 75, 76]
Intrastriatal DA release ++ [34, 37] not tested
Suppression of striatal interneurons +++ [40] not tested
Characteristic DA neuron firing in-vivo ++++ [40] not tested
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intermediate steps towards such trial have been taken in recent
studies on the transplantation of autologous iPSC-derived do-
pamine neurons in non-human primate model of Parkinson’s
disease [93, 94], showing the redundancy of the use of
immunosuppressiva.
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